News
CURX
5.25
-2.93%
-0.16
Curanex Pharmaceuticals Inc trading halted, news pending
TipRanks · 14h ago
Curanex Announces Reverse Stock Split to Maintain Nasdaq Listing
TipRanks · 2d ago
Weekly Report: what happened at CURX last week (0810-0814)?
Weekly Report · 3d ago
Weekly Report: what happened at CURX last week (0803-0807)?
Weekly Report · 08/10 10:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 08/05 12:05
Weekly Report: what happened at CURX last week (0727-0731)?
Weekly Report · 08/03 10:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/29 12:05
Weekly Report: what happened at CURX last week (0720-0724)?
Weekly Report · 07/27 10:09
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 07/22 12:05
Weekly Report: what happened at CURX last week (0713-0717)?
Weekly Report · 07/20 10:06
Weekly Report: what happened at CURX last week (0706-0710)?
Weekly Report · 07/13 10:07
Weekly Report: what happened at CURX last week (0629-0703)?
Weekly Report · 07/06 10:11
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 06/30 12:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 06/29 21:05
Weekly Report: what happened at CURX last week (0622-0626)?
Weekly Report · 06/29 10:06
Weekly Report: what happened at CURX last week (0615-0619)?
Weekly Report · 06/22 10:14
Weekly Report: what happened at CURX last week (0608-0612)?
Weekly Report · 06/15 10:15
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/09 21:06
Weekly Report: what happened at CURX last week (0601-0605)?
Weekly Report · 06/08 10:11
Weekly Report: what happened at CURX last week (0525-0529)?
Weekly Report · 06/01 10:15
More
Webull provides a variety of real-time CURX stock news. You can receive the latest news about CURANEX PHARMACEUTICALS INC through multiple platforms. This information may help you make smarter investment decisions.
About CURX
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).